Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling
Background: Ovarian cancer is the most lethal gynecological malignancy, and chemotherapy remains the cornerstone for ovarian cancer management. Due to the unsatisfactory prognosis, a better understanding of the underlying molecular carcinogenesis is urgently required. Methods: Assays for determining...
Main Authors: | Xu Yang, Mei Huang, Qin Zhang, Jiao Chen, Juan Li, Qian Han, Lu Zhang, JiaQi Li, Shuai Liu, YuLan Ma, Lan Li, Lei Yang, SiYing Zou, Bin Han |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-07-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/09636897211027819 |
Similar Items
-
HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
by: Heitmann, J.S, et al.
Published: (2022) -
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
by: Ombretta Melaiu, et al.
Published: (2014-01-01) -
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer
by: Deng L, et al.
Published: (2012-09-01) -
Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
by: Ombretta Melaiu, et al.
Published: (2017-01-01) -
Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases
by: Goricar Katja, et al.
Published: (2020-03-01)